• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by TRACON Pharmaceuticals Inc.

    10/31/24 4:15:03 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCON alert in real time by email
    S-8 POS 1 s-8_pos_am_333-216347.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on October 31, 2024

    Registration No. 333-201808

    Registration No. 333-209592

    Registration No. 333-216347

    Registration No. 333-223333

    Registration No. 333-229988

    Registration No. 333-236732

    Registration No. 333-253546

    Registration No. 333-258077

    Registration No. 333-263591

    Registration No. 333-270372

    Registration No. 333-277755

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-201808

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-209592

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216347

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223333

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-229988

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-236732

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-253546

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-258077

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263591

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270372

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-277755

     

    UNDER
    THE SECURITIES ACT OF 1933

    TRACON PHARMACEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    34-2037594

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

    124 Washington Street

    Foxborough, MA 02035

     

    92122

    (Address of Principal Executive Offices)

    (Zip Code)

    2011 Equity Incentive Plan

    Amended and Restated 2015 Equity Incentive Plan

    Amended and Restated 2015 Employee Stock Purchase Plan

    (Full title of the plans)


    Craig R. Jalbert

    President and Chief Executive Officer

    TRACON Pharmaceuticals, Inc.

    124 Washington Street

    Foxborough, MA 02035

    (Name and address of agent for service)

    (508) 543-1720

    (Telephone number, including area code, of agent for service)

    Copies to:
    Matthew T. Browne

    Anitha Anne
    Cooley LLP
    10265 Science Center Drive
    San Diego, California 92121
    (858) 550-6000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ¨

    Accelerated filer

    ¨

    Non-accelerated filer

    x

    Smaller reporting company

    x

    Emerging growth company

    ¨

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 (the “Post-Effective Amendment”) relates to the following registration statements of TRACON Pharmaceuticals, Inc. (the “Registrant”) on Form S-8 (each a “Registration Statement,” and collectively, the “Registration Statements”):

    ·

    Registration Statement on Form S-8 (No. 333-201808), registering 15,302 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), filed with the U.S. Securities and Exchange Commission (the “Commission”) on January 30, 2015, relating to the TRACON Pharmaceuticals, Inc. 2011 Equity Incentive Plan (the “2011 Plan”), TRACON Pharmaceuticals, Inc. Amended and Restated 2015 Equity Incentive Plan, as amended (the “2015 Plan”) and the TRACON Pharmaceuticals, Inc. Amended and Restated 2015 Employee Stock Purchase Plan, as amended (the “2015 ESPP”);

    ·

    Registration Statement on Form S-8 (No. 333-209592), registering 5,544 shares of Common Stock, filed with the Commission on February 19, 2016, relating to the 2015 Plan and 2015 ESPP;

    ·

    Registration Statement on Form S-8 (No. 333-216347), registering 4,022 shares of Common Stock, filed with the Commission on March 1, 2017, relating to the 2015 Plan and 2015 ESPP;

    ·

    Registration Statement on Form S-8 (No. 333-223333), registering 4,428 shares of Common Stock, filed with the Commission on March 1, 2018, relating to the 2015 Plan and 2015 ESPP;

    ·

    Registration Statement on Form S-8 (No. 333-229988), registering 7,468 shares of Common Stock, filed with the Commission on March 1, 2019, relating to the 2015 Plan and 2015 ESPP;

     

    ·

    Registration Statement on Form S-8 (No. 333-236732), registering 9,937 shares of Common Stock, filed with the Commission on February 28, 2020, relating to the 2015 Plan and 2015 ESPP;

     

     

     

    ·

    Registration Statement on Form S-8 (No. 333-253546), registering 32,793 shares of Common Stock, filed with the Commission on February 25, 2021, relating to the 2015 Plan and 2015 ESPP;

     

     

     

    ·

    Registration Statement on Form S-8 (No. 333-258077), registering 7,500 shares of Common Stock, filed with the Commission on July 22, 2021, relating to the 2015 Plan;

     

     

     

    ·

    Registration Statement on Form S-8 (No. 333-263591), registering 58,338 shares of Common Stock, filed with the Commission on March 16, 2022, relating to the 2015 Plan and 2015 ESPP;

     

     

     

    ·

    Registration Statement on Form S-8 (No. 333-270372), registering 69,376 shares of Common Stock, filed with the Commission on March 8, 2023, relating to the 2015 Plan and 2015 ESPP; and

     

     

     

    ·

    Registration Statement on Form S-8 (No. 333-277755), registering 123,175 shares of Common Stock, filed with the Commission on March 7, 2024, relating to the 2015 Plan and 2015 ESPP.

    The share numbers set forth above have been adjusted to reflect a 1-for-10 reverse stock split Common Stock effected on November 7, 2019 and a 1-for-20 reverse stock split of the shares of Common Stock effected on April 10, 2024.

     

    As previously disclosed in a Form 8-K filed with the Commission on July 30, 2024, the board of directors of the Registrant approved the dissolution and liquidation of the Registrant pursuant to a plan of dissolution (the “Plan of Dissolution”), subject to the approval of the Registrant’s stockholders. In connection with the foregoing, the Registrant has determined to terminate the offerings of the securities under the Registration Statements. Accordingly, the Registrant is filing this Post-Effective Amendment to terminate the effectiveness of the Registration Statements and to remove from registration any and all of the securities that remain unsold under the Registration Statements as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foxborough, State of Massachusetts, on this 31st day of October, 2024.

    TRACON PHARMACEUTICALS, INC.

    /s/ Craig R. Jalbert

    Craig R. Jalbert

    President and Chief Executive Officer

    (Principal Executive Officer and Principal Financial and Accounting Officer)

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment has been signed by the following persons in the capacities and on the dates indicated.

    Signature

    Title

    Date

    /s/ Craig R. Jalbert

    Director

    October 31, 2024

    Craig R. Jalbert

    No other person is required to sign this Post-Effective Amendment No. 1 in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     


    Get the next $TCON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TCON

    DatePrice TargetRatingAnalyst
    2/23/2022$10.00Outperform
    Baird
    More analyst ratings

    $TCON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baird initiated coverage on TRACON Pharmaceuticals with a new price target

    Baird initiated coverage of TRACON Pharmaceuticals with a rating of Outperform and set a new price target of $10.00

    2/23/22 4:50:05 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on TRACON Pharmaceuticals with a new price target

    Alliance Global Partners initiated coverage of TRACON Pharmaceuticals with a rating of Buy and set a new price target of $13.00

    6/4/21 8:08:23 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tracon Pharmaceuticals upgraded by BTIG Research with a new price target

    BTIG Research upgraded Tracon Pharmaceuticals from Neutral to Buy and set a new price target of $14.00

    4/16/21 8:36:58 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lazar David E.

    3 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

    5/13/24 5:00:43 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brown Scott B. was granted 3,500 shares, increasing direct ownership by 16% to 25,128 units (SEC Form 4)

    4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

    3/13/24 5:59:38 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Theuer Charles was granted 7,000 shares, increasing direct ownership by 2% to 406,417 units (SEC Form 4)

    4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

    3/13/24 5:56:13 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TRACON Pharmaceuticals Announces it Will Wind Down Operations

    SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

    7/30/24 4:44:46 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

    The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully

    7/1/24 9:00:00 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

    Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science c

    6/11/24 8:00:00 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    SEC Filings

    View All

    SEC Form 15-12G filed by TRACON Pharmaceuticals Inc.

    15-12G - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

    11/7/24 4:05:49 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

    EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

    11/4/24 12:15:04 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

    EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

    11/4/24 12:15:09 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Leadership Updates

    Live Leadership Updates

    View All

    TRACON Pharmaceuticals Announces it Will Wind Down Operations

    SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

    7/30/24 4:44:46 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors

    SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Carol Lam to its Board of Directors. "We are very pleased to welcome Carol to our Board of Directors," said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. "She brings a global perspective on technology development acquired through her extensive experience as deputy General Counsel

    10/13/21 8:00:00 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

    SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi. "We are very pleased to welcome Brenda to the senior management team at TRACON," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "

    7/20/21 8:05:00 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Financials

    Live finance-specific insights

    View All

    TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

    SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "With ENVASARC fully enrolled we are focused on leveraging our Product Development Platform to generate non-dilutive capital through either an additional license or by replacing a CRO and executi

    5/14/24 4:01:00 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

    SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. Date:May 14, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Conference Call:In order t

    5/7/24 4:01:00 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

    SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "We are on track to complete enrollment of 80 patients treated with single agent envafolimab in the ongoing pivotal ENVASARC trial later this quarter. We expect to report updated

    3/5/24 4:02:00 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    4/5/24 4:10:26 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    3/19/24 11:20:05 AM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care